Baseline Epidemiologic Assessment
Conditions
Keywords
Abuse, Misuse, Overdose
Brief summary
The main objectives of this study are to provide surveillance/descriptive data to (a) assess utilization of MorphaBond ER and selected comparators overall and by age group and census regions using nationally-projected quarterly drug dispensing data and (b) assess the scope and pattern of abuse and clinical outcomes for MorphaBond ER using nationally representative data or data from large geographic areas in different populations. Findings of this study will support the design of formal epidemiology assessment of the risks of addiction, overdose, and death outcomes associated with MorphaBond ER and appropriate comparators in the future.
Detailed description
The study started after the launch of MorphaBond ER in October 2017 and will continue until September 2020 and the final study report will be submitted to the FDA by December 2020. This is an observational study that will provide descriptive data on the utilization and abuse of MorphaBond ER and related outcomes (addiction, misuse, abuse, overdose, overdose-related deaths) for MorphaBond ER and selected comparators in response to the US-FDA's post-marketing requirement (PMR 2961-9 for MorphaBond ER). No investigational products or pharmaceutical agents will be provided or administered for the purpose of this study. Multiple data sources, representing different populations and large geographic areas in the US, will be utilized to study the patterns of MorphaBond ER utilization and abuse and related outcomes. The overall purpose of this study is to collect meaningful baseline data to support subsequent studies for formal epidemiologic assessment of abuse deterrence of MorphaBond ER as required by the FDA.
Interventions
DRUGMorphaBond ER
This was a retrospective, non-interventional study. Previous users of branded and generic products (tablets or capsules) with ER and immediate release (IR) release type formulations of oxycodone, oxymorphone, hydromorphone and morphine (except MorphaBond).
DRUGComparator Drug
This was a retrospective, non-interventional study. Previous users of the MorphaBond ER brand of ER morphine sulfate with A-D labeling, by prescription or non-prescription.
Sponsors
Daiichi Sankyo
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Male or female * MorphaBond ER users or relevant comparator users
Exclusion criteria
* Not applicable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rates of misuse of MorphaBond Extended Release (ER) vs. comparators | October 2017 through September 2020 |
| Quarterly number of MorphaBond Extended Release (ER) dosage unit dispensed | October 2017 through September 2020 |
| Percentage and rates of abuse/abuse-related outcomes of MorphaBond Extended Release (ER) vs. comparators | October 2017 through September 2020 |
| Overall mortality rates and opioid overdose death rates of MorphaBond Extended Release (ER) vs. comparators | October 2017 through September 2020 |
| Rates of addiction of MorphaBond Extended Release (ER) vs. comparators | October 2017 through September 2020 |
| Overdose rates of MorphaBond Extended Release (ER) vs. comparators | October 2017 through September 2020 |
Secondary
| Measure | Time frame |
|---|---|
| Number and proportion of abuse-related outcomes by routes of administration (e.g. ingestion, inhalation, etc). | October 2017 through September 2020 |
Countries
United States
Outcome results
None listed